FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 360:623-625 February 5, 2009 Number 6 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Tol, J. PubMed Citation

During the past few years, the outlook for patients with colorectal cancer has brightened considerably. Fluorouracil, an inhibitor of thymidylate synthase (and therefore DNA synthesis), was until recently the only effective systemic treatment for this disease. Fluorouracil is usually administered with leucovorin (i.e., folinic acid), which appears to stabilize the binding of the drug to thymidylate synthase. Since 1996, three new cytotoxic drugs — capecitabine (an oral fluoropyrimidine), irinotecan (a topoisomerase I inhibitor that blocks DNA repair), and oxaliplatin (an inhibitor of DNA replication and possibly a down-regulator of the expression of thymidylate synthase) — have been introduced into clinical . . . [Full Text of this Article]

Source Information

From the Dana–Farber Cancer Institute, Boston.

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.